|
Slovakia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Slovakia Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Slovakia .
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Slovak pharmaceutical and healthcare industry.
Competitive intelligence, Slovak pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Slovak market.
The Slovakia Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- 2013 covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Slovakia Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Slovak pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Slovakia to test other views – a key input for successful budgeting and strategic business planning in the Slovak pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Slovak Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Slovakia .
- Exploit The Latest Competitive Slovak Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Slovakia .
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- 2013 for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Slovakia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| SWOT Analysis |
| Slovakia Pharmaceuticals Industry SWOT |
| Slovakia Political SWOT |
| Slovakia Economicsl SWOT |
| Slovakia Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Regional Pharmaceutical Business Environment Ratings |
| Limits Of Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Slovakia – Market Summary |
| Regulatory Regime |
| Generics Legislation |
| Recent Regulatory Developments |
| Intellectual Property Regime |
| IP Deficiencies |
| Pricing Regime |
| Reimbursement Regime |
| Pricing Developments |
| Eurozone Entry |
| Table: Slovakia – Exchange Rate Policy |
Chapter - Industry Trends And Developments |
| Epidemiology |
| Table: Main Causes Of Mortality And Morbidity In Slovakia, 2006 |
| Table: Disease Burden In CEE |
| Healthcare Sector |
| Healthcare Sector Reforms |
| Health Insurance |
| Recent Health Insurance Developments |
| Healthcare Funding Crisis |
| Regional Healthcare Sector Developments |
| Pharmaceutical Industry |
| Recent Pharmaceutical Industry Developments |
| Research And Development |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Slovakia – Drug Expenditure Indicators, 2004-2013 |
| Key Growth Factors – Industry |
| Table: Slovakia – Health Market Indicators, 2004-2013 |
| Key Growth Factors – Macroeconomic |
| Table: Slovakia - Economic Activity |
| Prescription Market Forecast |
| Table: Slovakia – Prescription Market Indicators, 2004-2013 |
| OTC Market Forecast |
| Table: Slovakia – OTC Market Indicators, 2004-2013 |
| Patented Market Forecast |
| Table: Slovakia – Patented Market Indicators, 2004-2013 |
| Generic Drug Market Forecast |
| Table: Slovakia – Generic Market Indicators, 2004-2013 |
| Export/Import Forecasts |
| Table: Slovakia – Pharmaceutical Trade Indicators, 2004-2013 |
| Medical Devices Forecast |
| Table: EU Medical Device Classifications |
| Table: Slovakia Medical Device Market Forecast , 2004 - 2012 |
| Other Healthcare Data Forecasts |
| Table: Slovakia – Other Healthcare Indicators, 2004-2013 |
| Key Risks To BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Company Monitor |
| Multinational Company Profiles |
| GlaxoSmithKline (GSK) |
| Sanofi-Aventis |
| Pfizer |
| Novartis |
| Merck & Co |
| Roche |
| Indigenous Company Profiles |
| Zentiva (incorporating Sicomed) |
| Biotika |
| Hoechst-Biotika |
| Imuna Pharma |
Chapter - Country Snapshot: Slovakia Demographic Data |
| Section 1: Population: |
| Table: Demographic Indicators |
| Table: Rural/Urban Breakdown |
| Section 2: Education & Healthcare |
| Table: Education |
| Table: Healthcare: Vital Statistics |
| Table: Employment Indicators |
| Table: Consumption And Stratification |
| Table: Wages Per Year |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Slovakia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Slovakia’s pharmaceutical market will represent sound prospects for multinational pharmaceutical companies over the next five years. Despite relatively mediocre total sales of US$2.04bn in 2008, per capita spending has been strong, averaging double-digit growth over the past four years.
Following eurozone accession at the start of 2009 and in line with the global economic outlook, BMI has updated its forecast model with the latest macroeconomic variables. As a result, over the next five years, sales of pharmaceuticals, which include prescription drugs and over-the-counter (OTC) medicines, should increase from to US$2.60bn, representing a compound annual growth rate (CAGR) of 4.96%. In local currency growth should be considerably stronger, with a CAGR of 8.15%.
The underdeveloped nature of the over-the-counter sector in Slovakia means that prescription drugs will remain the dominant sector. The market is showing a maturing trend in line with healthcare improvements, with the use of anti-infectives declining rapidly. The importance of cardiovascular treatments has decreased over the past five years. The major growth segment in future is likely to be antineoplastics, which should prosper on the back of increased per capita spending.
In terms of our Pharmaceutical Business Environment Rankings, Slovakia is placed in second position with the Central and Eastern Europe region for Q209. Strong market dynamics are boosted by relatively strong risk scores in terms of both the regulatory environment and economic and political climate. The country is viewed as generally complying with international requirements for approvals as well as intellectual property (IP) protection. Additionally, the alignment of procedures with EU legislation is a positive step towards a higher degree of transparency in pharmaceutical and healthcare legislation. Negative demographics factors prevent a higher score.
Debt remains a key concern in the Slovakian health system. The country's state-run hospitals registered a debt of EUR196.2mn (US$288.5mn) at the end of 2008, increasing by 1.2% year-on-year (y-o-y). The cabinet has approved a debt settlement plan which should be implemented in 2009. Debts will be paid with refundable financial aid, with a 15 year repayment plan.
Slovkia started introducing a new e-health system in early 2009, which is part of a project aimed at introducing tolls such as e-records and e-prescriptions. Expected benefits from the new system are due to be realised in the second half of 2010.
BMI’s Burden of Disease Database (BoDD) shows that Slovakia is among the healthiest countries in the region, with 15,302 disability-adjusted life years (DALYs) lost to all diseases and injuries in 2008. Through to 2030 widespread improvements in care provisions should cause a significant decrease in this figure.
|
Slovakia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |